Tag Archive for: HRR
ASCO GU 2025: Impact of Homologous Recombination Repair Alterations on Survival Outcomes in Metastatic Hormone-Sensitive Prostate Cancer (BRCA, ATM, CDK12,…)
/0 Comments/in Observational, Retrospective studies/by MaxTargeting LIG1 with PARP Inhibitors: E New Target Identified Using CRISPR
/0 Comments/in CRISPR, PARPi, Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
abiraterone acetate ADC ADT AI ai in healthcare alphafold antibody-drug conjugate apalutamide artificial intelligence ATM bispecific antibody bone metastasis BRCA cancer immunotherapy cancer treatment chemotherapy clinical trial clinical trials crispr darolutamide diet drug discovery drug repurposing drug resistance enzalutamide gut microbiome hormone therapy HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic cancer metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC neuroendocrine prostate cancer oncology personalized medicine prostate cancer PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- IMGS-101: Phase 1/2 Clinical Trial Begins for Hypoxia-Reversing Agent in Prostate Cancer March 8, 2025
- SECuRE Trial Update: Promising Results in Metastatic Castration-Resistant Prostate Cancer March 7, 2025
- Phase 3 Trial: 225-Ac-PSMA-617 + ARPI vs SOC March 6, 2025
- FG-3246 Advances to Phase 2 Trial in Prostate Cancer After Promising Early Results March 6, 2025